| Order.co Named One of Inc.’s 2025 Best Workplaces – Here’s What Sets It Apart |
Globe Newswire |
06/17 |
08:17 |
| OM System Announces OM-5 Mark II Mirrorless Camera, YouTube First Look Video OM5 Mark II Adventure Ready Camera, More Info at B&H |
Globe Newswire |
06/17 |
02:00 |
| EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL |
Globe Newswire |
06/15 |
19:30 |
| Sunny Mining achieves breakthrough AI-driven technology,Becoming a profitable milestone in the cloud mining industry |
Globe Newswire |
06/13 |
18:15 |
| Cumulus Media’s Westwood One Presents Exclusive Multiplatform Audio Coverage of the 2025 NCAA® Men’s College World Series Championships |
Globe Newswire |
06/12 |
14:00 |
| NevGold Extends Oxide Gold-Antimony Mineralization Over 1.7 Kilometers at Cadillac Valley Target: 2.28 g/t AuEq Over 30.5 Meters (1.29 g/t Au And 0.22% Antimony) Within 1.61 g/t AuEq Over 61.0 Meters (1.08 g/t Au And 0.12% Antimony) |
Globe Newswire |
06/12 |
06:00 |
| Diabetic Nephropathy Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 12+ Companies and 15+ Therapies | DelveInsight |
Globe Newswire |
06/10 |
13:00 |
| Only 11% of Teams Have Scaled AI: Order.co’s 2025 Benchmark Report Reveals Urgent Gap in Procurement, Finance, and Ops |
Globe Newswire |
06/10 |
08:00 |
| Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress |
Globe Newswire |
06/09 |
19:30 |
| NetExperience Introduces New Zero Touch Provisioning Application for WiFi Installers |
Globe Newswire |
06/09 |
10:00 |
| Magnite Integrates Anoki ContextIQ Platform and AI Copilot to Bring Scene Level Targeting to CTV |
Globe Newswire |
06/05 |
08:00 |
| NevGold Adds More Significant Oxide Gold-Antimony Results: 7.04 g/t AuEq Over 15.2 Meters (6.37 g/t Au And 0.15% Antimony) Within 4.14 g/t AuEq Over 29.0 Meters (3.56 g/t Au And 0.13% Antimony), and Expands Gold-Antimony Mineralization Over 400 Meters Along Strike at the Limousine Butte Project, Nevada |
Globe Newswire |
06/04 |
17:36 |
| NevGold Adds More Significant Oxide Gold-Antimony Results: 1.47 g/t AuEq Over 74.7 Meters (0.23% Antimony And 0.45 g/t Au), Including 3.59 g/t AuEq Over 18.2 Meters (0.60% Antimony And 0.92 g/t Au), and Also Including 4.61 g/t AuEq Over 6.0 Meters (0.96% Antimony And 0.31 g/t Au) at the Limousine Butte Project, Nevada |
Globe Newswire |
06/03 |
16:15 |
| Vic.ai Launches VicPay™, Vendor Portal, and VicAgents™, Introducing Agentic AI Partners for Enterprise Finance |
Globe Newswire |
06/03 |
06:30 |
| Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors |
Globe Newswire |
06/02 |
19:30 |
| Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report |
Globe Newswire |
06/02 |
19:30 |
| Entertainment Partners to Acquire CASHét Strengthening End-to-End Production Finance Offerings |
Globe Newswire |
06/02 |
15:30 |
| Cumulus Media's Westwood One Presents Exclusive Multiplatform Audio Coverage of the 2025 NCAA® Women's College World Series |
Globe Newswire |
05/28 |
15:03 |
| xSuite North America to Host 2025 User Conference in Boston |
Globe Newswire |
05/28 |
08:25 |
| ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAR |
Globe Newswire |
05/25 |
12:11 |
| Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 |
Globe Newswire |
05/22 |
20:15 |
| Graphitic Energy and Technip Energies Form Collaboration to Scale Clean Hydrogen Technology |
Globe Newswire |
05/21 |
09:00 |
| Media Agencies Under Pressure, Turning to AI to Strengthen Financial Health and Cash Flow, AvidXchange Survey Reveals |
Globe Newswire |
05/20 |
10:00 |
| Corcentric Accelerates Intelligent AP Automation deployment for its Procure-to-Pay Customers |
Globe Newswire |
05/20 |
09:02 |
| NovelMed’s Phase II Data in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Shows Best-in-Class Efficacy as Monotherapy |
Globe Newswire |
05/19 |
11:48 |
